Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. [PDF]
Kozaki R +8 more
europepmc +1 more source
Targeting Cell Signalling Pathways: A Short Review on Tyrosine Kinase Inhibitors
This short review discusses about tyrosine kinase inhibitors (TyKI) as a potential targeting cell signalling pathway blocker playing active role as anticancer drugs.
Tasleem, Nasreen Sultana, Sushma Desai
core +1 more source
Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures". [PDF]
Darragh AC +5 more
europepmc +2 more sources
A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B‑Cell Signaling
Einav Ratzon +7 more
doaj +1 more source
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor. [PDF]
Bar-Or A +9 more
europepmc +1 more source
Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy. [PDF]
Park HY +5 more
europepmc +1 more source
Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy
British Journal of Haematology, Volume 209, Issue 5, Page 2302-2306, November 2026.
Isacco Ferrarini +19 more
wiley +1 more source
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. [PDF]
Sinha M +28 more
europepmc +1 more source
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. [PDF]
Cherng HJ +14 more
europepmc +1 more source

